LAVA Therapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
LAVA Therapeutics NV updated its corporate info in an 8-K filing on Sept 30, 2025.
AI Summary
LAVA Therapeutics N.V. filed an 8-K on September 30, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at Yalelaan 62, Utrecht, The Netherlands, and provides its telephone number as +31 85 016 3100. The company was formerly known as LAVA Therapeutics BV until a name change on January 15, 2021.
Why It Matters
This 8-K filing provides updated corporate information and addresses for LAVA Therapeutics N.V., which is important for investors and stakeholders to ensure they have the correct contact and location details for the company.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain information that suggests immediate financial or operational risk.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- Yalelaan 62, Utrecht, The Netherlands (location) — Principal executive offices
- +31 85 016 3100 (phone_number) — Registrant's telephone number
- LAVA Therapeutics BV (company) — Former company name
- January 15, 2021 (date) — Date of name change
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 30, 2025.
What is the principal executive office address for LAVA Therapeutics N.V.?
The principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands.
What is the telephone number for LAVA Therapeutics N.V.?
The registrant's telephone number is +31 85 016 3100.
What was LAVA Therapeutics N.V. formerly known as?
The company was formerly known as LAVA Therapeutics BV.
When did the name change from LAVA Therapeutics BV to LAVA Therapeutics N.V. occur?
The date of the name change was January 15, 2021.
Filing Stats: 1,547 words · 6 min read · ~5 pages · Grade level 15.5 · Accepted 2025-09-30 07:30:44
Filing Documents
- tm2526706d2_8k.htm (8-K) — 33KB
- tm2526706d2_ex99-1.htm (EX-99.1) — 15KB
- tm2526706d2_ex99-1img01.jpg (GRAPHIC) — 6KB
- 0001104659-25-094744.txt ( ) — 227KB
- lvtx-20250930.xsd (EX-101.SCH) — 3KB
- lvtx-20250930_lab.xml (EX-101.LAB) — 33KB
- lvtx-20250930_pre.xml (EX-101.PRE) — 22KB
- tm2526706d2_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 30, LAVA Therapeutics N.V. (the "Company") issued a press release announcing its intention to cancel the Extraordinary General Meeting of Shareholders (the "EGM") scheduled to occur on September 30, 2025 to consider and approve certain matters related to the Company's previously announced transaction with XOMA Royalty Corporation ("XOMA"), pursuant to which XOMA made an offer to purchase all of the issued and outstanding common shares in the capital of the Company (the "Transaction"). The EGM is expected to be reconvened by early November 2025. The meeting date, record date and location for the reconvened EGM will be determined and announced by the Company at a later date. Votes already cast by shareholders in respect of the EGM will not count towards the voting outcome on the matters proposed to the reconvened EGM. Shareholders as of the record date for the reconvened EGM will have to cast their votes (or cast their votes again, as the case may be) for their votes to count towards the voting outcome. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 30, 2025. 104 Cover page interactive data file (embedded within the inline XBRL document). Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking "could", "will", "may", "expect", "should", "plan", "intend", "estimate", "potential", "suggests", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this Form 8-K and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. As a result, a number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the risk that the Transaction may not be completed in a timely manner, or at all, which may adversely affect the Company's business and the price of its common shares; the risk that the terms of the Transaction may be revised to be less favorable to the Company's shareholders; the delay or failure of the terms of the Transaction to be revised or of the offer conditions to be satisfied (or waived), including insufficient common shares of the Company being tendered in the offer, any of which delays may impact the amount payable to the Company's shareholders in the Transaction; the possibility that competing offers will be made; significant costs associated with the Transaction; the risk that any shareholder or other litigation in connection with the Transaction may result in significant costs of defense, indemnification and liability; th
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LAVA Therapeutics N.V. Date: September 30, 2025 By: /s/ Fred Powell Fred Powell Chief Financial Officer